SCHEMBL8959382

SCHEMBL8959382

COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@]13CC[C@@]2(OC(C)=O)[C@H](OC(C)=O)C3

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.57
CYP3A4 P08684 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
MAPT P10636 3/20 0.48
TP53 P04637 1/20 0.48
LMNA P02545 6/20 0.46
RECQL P46063 2/20 0.46
HSD17B1 P14061 2/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
BRCA1 P38398 1/20 0.44
HSD17B10 Q99714 1/20 0.43
PGR P06401 2/20 0.41
SLC6A3 Q01959 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
NR3C1 P04150 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8959334 0.93 SMN1; SMN2 (0.57) ESR1CYP3A4SMN1; SMN2MAPTTP53
SCHEMBL8959380 0.93 SMN1; SMN2 (0.57) ESR1CYP3A4SMN1; SMN2MAPTTP53
SCHEMBL9725124 0.88 ESR1 (0.48) ESR1CYP3A4SMN1; SMN2MAPTTP53
SCHEMBL8959396 0.88 ESR1 (0.48) ESR1CYP3A4SMN1; SMN2MAPTTP53
SCHEMBL8959357 0.88 ESR1 (0.48) ESR1CYP3A4SMN1; SMN2MAPTTP53
SCHEMBL9725174 0.87 ESR1 (0.47) ESR1CYP3A4SMN1; SMN2MAPTTP53
SCHEMBL8959340 0.87 ESR1 (0.47) ESR1CYP3A4SMN1; SMN2MAPTTP53
SCHEMBL9725135 0.83 ESR1 (0.54) ESR1CYP3A4SMN1; SMN2MAPTTP53
SCHEMBL9627471 0.83 ESR1 (0.54) ESR1CYP3A4SMN1; SMN2MAPTTP53
SCHEMBL8959393 0.81 ESR1 (0.42) ESR1CYP3A4SMN1; SMN2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0430386-B1 14Alpha, 17alpha bridged 16-hydroxyestratrienes SCHERING AG (DE) 1995-05-03 EP claimed
EP-0430386-A1 14Alpha, 17alpha bridged 16-hydroxyestratrienes SCHERING AKTIENGESELLSCHAFT (DE) 1991-06-05 EP claimed
US-5529993-A UROGENITAL DISORDERS; CONTRACEPTIVES SCHERING AKTIENGESELLSCHAFT (DE) 1996-06-25 US disclosed
EP-0430386-B1 14Alpha, 17alpha bridged 16-hydroxyestratrienes SCHERING AG (DE) 1995-05-03 EP disclosed
EP-0430386-A1 14Alpha, 17alpha bridged 16-hydroxyestratrienes SCHERING AKTIENGESELLSCHAFT (DE) 1991-06-05 EP disclosed